Intra-individual Dose Escalation of Abiraterone According to Its Plasma Exposure in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer: Results of the OPTIMABI Trial.

Alexandre J, Oudard S, Golmard L, Campedel L, Mseddi M, Ladoire S, Khalil A, Maillet D, Tournigand C, Pasquiers B, Goirand F, Berthier J, Guitton J, Dariane C, Joly F, Xylinas E, Golmard JL, Abdoul H, Puszkiel A, Decleves X, Carton E, Thomas A, Vidal M, Huillard O, Blanchet B

Open source

DOI: 10.1007/s40262-024-01396-x
Published: 2024 Jul
Container: Clinical pharmacokinetics
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s40262-024-01396-x,
  title = {Intra-individual Dose Escalation of Abiraterone According to Its Plasma Exposure in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer: Results of the OPTIMABI Trial.},
  author = {Alexandre J and Oudard S and Golmard L and Campedel L and Mseddi M and Ladoire S and Khalil A and Maillet D and Tournigand C and Pasquiers B and Goirand F and Berthier J and Guitton J and Dariane C and Joly F and Xylinas E and Golmard JL and Abdoul H and Puszkiel A and Decleves X and Carton E and Thomas A and Vidal M and Huillard O and Blanchet B},
  year = {2024},
  journal = {Clinical pharmacokinetics},
  doi = {10.1007/s40262-024-01396-x},
  url = {https://doi.org/10.1007/s40262-024-01396-x}
}

RIS

TY  - JOUR
TI  - Intra-individual Dose Escalation of Abiraterone According to Its Plasma Exposure in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer: Results of the OPTIMABI Trial.
AU  - Alexandre J
AU  - Oudard S
AU  - Golmard L
AU  - Campedel L
AU  - Mseddi M
AU  - Ladoire S
AU  - Khalil A
AU  - Maillet D
AU  - Tournigand C
AU  - Pasquiers B
AU  - Goirand F
AU  - Berthier J
AU  - Guitton J
AU  - Dariane C
AU  - Joly F
AU  - Xylinas E
AU  - Golmard JL
AU  - Abdoul H
AU  - Puszkiel A
AU  - Decleves X
AU  - Carton E
AU  - Thomas A
AU  - Vidal M
AU  - Huillard O
AU  - Blanchet B
PY  - 2024
JO  - Clinical pharmacokinetics
DO  - 10.1007/s40262-024-01396-x
UR  - https://doi.org/10.1007/s40262-024-01396-x
ER  -

APA

J, A., S, O., L, G., L, C., M, M., S, L., A, K., D, M., C, T., B, P., F, G., J, B., J, G., C, D., F, J., E, X., JL, G., H, A., A, P., X, D., E, C., A, T., M, V., O, H., & B, B. (2024). Intra-individual Dose Escalation of Abiraterone According to Its Plasma Exposure in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer: Results of the OPTIMABI Trial.. Clinical pharmacokinetics. https://doi.org/10.1007/s40262-024-01396-x

Source records

pubmed · retrieved 2026-09-26T11:19:04.005Z